Trachoma Clinical Trial
Official title:
A Randomised Controlled Trial of Non-absorbable (Silk) Sutures Verses Absorbable (Vicryl) Sutures During the Surgical Treatment of Trachomatous Trichiasis
Trachoma is the leading infectious cause of blindness worldwide. Recurrent infection by Chlamydia trachomatis causes in-turning of the eyelids / lashes (trichiasis), leading to corneal damage and blindness. The WHO recommends corrective eyelid surgery for trichiasis. Unfortunately, trichiasis frequently returns following surgery. The purpose of this study is to compare the outcome of surgery (at one and two years) for trichiasis using two currently used alternative suture types: non-absorbable (silk) and absorbable (vicryl). We, the researchers, hypothesise that the supportive presence of the absorbable suture for a longer period produces more stable wound healing, leading to a better outcome.
Primary outcome measure:
Recurrent trichiasis, defined as one or more eyelashes touching the globe or evidence of
epilation (lash stubs) on examination, or a history of repeat trichiasis surgery since the
baseline surgery, at one year.
Justification of primary outcome:
The aim of surgery is a permanent solution for trichiasis. If a patient has eyelashes
touching the eyeball or there is clinical evidence that they are epilating to prevent this
or they have required repeat trichiasis surgery, surgery can be deemed a failure.
Analysis of primary outcome measure
Intention to treat analysis of risk factors for recurrence.
Primary analysis of primary outcome:
It is expected that the important baseline characteristics (those that are known to affect
the risk of recurrence) will be balanced between the two arms by stratified (for operating
surgeon) randomisation. If this is found to be the case, the outcome of the surgery in the
two arms will be compared in an unadjusted logistic regression model for recurrent
trichiasis at one year. If the arms are found to be substantially imbalanced with respect
to, pre-operative severity, gender or age, an appropriately adjusted logistic regression
model will be used.
Individuals will be considered to be recurrent trichiasis cases if they have developed
recurrent trichiasis at anytime during the one year follow-up period.
Secondary analysis of primary outcome:
1. Effect modification We will assess effect modification of the intervention on
recurrence at one year with the following factors by including an interaction term with
treatment arm in the logistic regression model.
1. Operating surgeon
2. Pre-operative severity
3. Sex
4. Age group
5. Conjunctival (papillary) inflammation
6. Surgical complications
2. Analysis of risk factors for recurrence:
A multivariate logistic regression model will be used to identify potential explanatory
factors for recurrent trichiasis at one year, in addition to the randomised suture type
allocation. Other factors which will be examined in a model of recurrent trichiasis
will include
1. pre-operative disease severity
- trichiasis
- entropion
- corneal opacity
2. surgeon
3. infection status at baseline and follow up timepoints
4. inflammation status at baseline and follow up timepoints
5. whether epilation is being practised
6. sex
7. age
8. geographic location of patient's home
9. literacy
10. body mass index
11. eye dryness
- symptoms
- signs
3. Impact of intervention on time-to-first-recurrence. Kaplan-Meier analysis will be used
to plot the survival curves for both treatment arms up to the final visit at 2 years.
Cox regression will be used to assess the impact of the intervention on time to first
recurrence. The hazard ratio will be estimated with Cox regression, adjusting for
substantial baseline imbalances if appropriate.
4. Recurrence at two years Intention-to-treat analysis will be used to assess the impact
of the intervention on failure at 2 years. Failure will be defined as one or more
eyelashes touching the globe or evidence of epilation (lash stubs) on examination, or a
history of repeat trichiasis surgery since the baseline surgery, at either one year
and/or two year follow-up visits.
Secondary outcome measures
1. Lashes touching the eyeball The effect of the intervention on the number of lashes
touching at one, and two years, respectively, will be analysed using zero inflated
Poisson regression (i.e. treating number of lashes as a continuous variable)
2. Entropion grade The effect of the intervention on the degree of entropion will be
analysed by ordered logistic regression
3. Conjunctivilisation of the lid margin grade The effect of the intervention on the
degree of conjunctivilisation will be analysed by ordered logistic regression
4. Clinical evidence of epilation The effect of the intervention on clinical evidence of
epilation will be assessed at one and two years respectively with logistic regression.
In addition, Cox regression will be used to analyse time-to-first evidence of
epilation.
5. Repeat surgery The effect of the intervention on the proportion with repeat surgery
will be assessed at one and two years respectively with logistic regression. In
addition, Cox regression will be used to analyse time-to-first evidence of first repeat
surgery.
6. Recurrence (lashes touching the eyeball, clinical evidence of epilation, repeat
surgery) + history of epilation A secondary definition of recurrence will incorporate
self-reported history of epilation. The primary analyses will be repeated with this
definition of recurrence.
7. Corneal opacification (CO) (categorical variable)
1. Descriptive measures of the baseline severity of CO
2. Description of the change in CO between baseline and one and two year follow up
time-points.
3. Ordered logistic regression analysis for factors associated with change in CO at
one year and two years, respectively, including to identify factors associated
with it, such as suture type and inflammation.
8. Visual acuity (VA) (categorical variable) The effect of the intervention on the visual
acuity (logMAR score) at 12 and 24 months will be analysed by linear regression.
9. Surgical complications
Surgical complications other than recurrence, such as granuloma, incomplete lid
closure, inflammation (secondary to either of the two sutures materials) and infection
can occur. Descriptive statistics, with significance testing will be used to compare
the rates of occurrence of all complications and individual complications at any time
during the study period between the two arms of the study.
10. Patient satisfaction
Patients are asked the following questions on the follow up questionnaires that indicate
their satisfaction with the procedure:
1. Do you think your vision is worse, the same or better than before your surgery?
2. Do you have eye pain?
3. If you have eye pain is it worse, the same or better than before the operation?
4. Do your eyes water?
5. Did you find the surgery painful?
6. If the eyelashes have returned or will return would you seek further surgery?
The proportion answering 'yes' to each of these questions will be compared between the two
arms of the trial.
Additionally the answers to questions (b) and (d) will be compared between baseline
(pre-operative) and the answer given at each time point within each arm.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03676140 -
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
|
Phase 3 | |
Completed |
NCT01949454 -
Fluorometholone as Ancillary Therapy for TT Surgery
|
N/A | |
Completed |
NCT01202331 -
Tripartite International Research for the Elimination of Trachoma
|
Phase 4 | |
Completed |
NCT05634759 -
Enhancing the A in SAFE for Trachoma
|
Phase 4 | |
Recruiting |
NCT04185402 -
Azithromycin Reduction to Reach Elimination of Trachoma
|
Phase 4 | |
Active, not recruiting |
NCT00886015 -
Modified Instrumentation for Surgery to Correct Trichiasis
|
Phase 3 | |
Completed |
NCT00792922 -
Partnership for Rapid Elimination of Trachoma
|
Phase 4 | |
Completed |
NCT00221364 -
Trachoma Elimination Follow-up
|
Phase 4 | |
Completed |
NCT00322972 -
Trachoma Amelioration in Northern Amhara (TANA)
|
Phase 4 | |
Withdrawn |
NCT00286026 -
Azithromycin in Control of Trachoma II
|
Phase 4 | |
Completed |
NCT00347763 -
Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania
|
Phase 4 | |
Terminated |
NCT04002726 -
App-based Versus Slide-based Inter-grader Agreement (IGA) Test for Trachoma Graders
|
N/A | |
Terminated |
NCT03997487 -
Smartphone App for Taking Images of Conjunctivae
|
N/A | |
Not yet recruiting |
NCT06289647 -
Azithromycin Reduction to Reach Elimination of Trachoma B
|
Phase 4 | |
Withdrawn |
NCT02655432 -
Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population
|
Phase 0 | |
Completed |
NCT01767506 -
A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
|
N/A | |
Completed |
NCT00618449 -
Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger
|
Phase 4 | |
Completed |
NCT00356720 -
Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma
|
Phase 3 | |
Completed |
NCT03813069 -
Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma
|
Phase 2 | |
Recruiting |
NCT03335072 -
Kebele Elimination of Trachoma for Ocular Health
|
Phase 4 |